Search
Stoke Therapeutics Inc
STOKAdd to Watchlist
32.710USD
-0.010-0.03%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
2.04BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of Stoke Therapeutics Inc is 9.00, ranking 14 out of 387 in the Biotechnology & Medical Research industry. The average price target is 33.50, with a high of 39.00 and a low of 24.00.
Analyst Rating
Based on
12
analysts
Strong Buy
Current Rating
45.100
Target Price
+37.84%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Stoke Therapeutics Inc
STOK
12
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Stoke Therapeutics Inc's expected revenue for the next quarter?
Stoke Therapeutics Inc's expected revenue is 6.04M.
What is Stoke Therapeutics Inc's price target?
Analysts forecast that Stoke Therapeutics Inc's price target is USD 33.50, with the highest forecast at USD 39.00 and the lowest forecast at USD 24.00.
How have Stoke Therapeutics IncSTOK's recent earnings per share performed?
The market expectation was USD -0.79, while Stoke Therapeutics IncSTOK's earnings per share (EPS) for the previous quarter was USD -0.98. EPS for the next quarter is expected at USD -0.78.
What is the analyst rating for Stoke Therapeutics Inc?
Based on the ratings of Stoke Therapeutics Inc's stock from 12 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.